Introduction
Breast cancer is the most common cancer among women worldwide and accounts for 18% of all female malignancies. Infiltrating duct carcinoma is the most frequent histological type of breast cancer, accounting for B68% of patients (Subhawong et al., 2009) . In Egypt, breast cancer constitutes 33% of all female cancers in the Egyptian National Cancer Institute (EL Bolkainy et al., 2005) .
Breast cancer is an important cause of morbidity and mortality among women. It represents the second leading cause of cancer deaths in female individuals (after skin cancer). The estimated annual incidence of breast cancer worldwide is about 1 million patients (22% of all cancers in the world in 2000) (Dumitrescu and Cotarla, 2005) .
CD10 is a zinc-dependent peptidase (metalloproteinase), which degrades a variety of bioactive peptides. Earlier studies suggested that CD10 expression in tumor stroma is associated with biological aggressiveness of the tumor. Expression of CD10 in the stroma of invasive breast carcinoma is associated with ER-negativity, higher tumor grade, and decreased patient survival, and it is most significant in the node-negative subset. Hence, CD10 constitutes a clinically important prognostic marker and a potential target for the development of novel therapies (Makretsov et al., 2007) .
The aim of the study is to evaluate the immunohistochemically expression of stromal CD10 in all studied patinets and to correlate the obtained statistically analyzed results with histopathological variables and with the available previously performed hormone profile of all studied patients.
Materials and methods
The material of this study included 50 paraffin blocks obtained from female patients with duct carcinoma in situ and invasive duct carcinoma, by either breast lumpectomy or radical mastectomy. All patients were studied histologically and graded according to Elston/Nottingham (Elston and Ellis, 2002) modification of Bloom-Richardson system and then studied immunohistochemically using monoclonal antibodies against CD10.
These blocks were obtained from private laboratories within the period from January 2000 to December 2009. The clinical data were obtained from the pathology reports of the patients. These data included age of patients, all clinical data, the maximal diameter of tumor, and available previously performed hormone profile.
The previously performed hormone profile included immunohistochemical expression of estrogen, progesterone, and Her2/neu receptors. Estrogen and progesterone receptor immunostaining were scored as negative, weak, moderate, and strong. Her2/neu receptor immunostaining was scored as negative, weak, and strong. It is noteworthy that Her2/neu expression in duct carcinoma in-situ patients had no clinicopathological indication and that Her2/neu expression in patients with extensive duct carcinoma in situ with focal invasion was considered for the areas showing stromal invasion only (Ivković-Kapicl et al., 2007) .
Each paraffin block was recut using rotatory microtome into 5 mm thickness and then mounted on glass slides to be stained by hematoxylin and eosin for histopathological examination and on charged slides for CD10 immunostaining.
Histopathological evaluation (Elston and Ellis, 1991) According to Elston/Nottingham modification of Bloom-Richardson system (Elston and Ellis, 1991) , all studied patients with invasive duct carcinoma were graded as grade I, II, and III. Elston/Nottingham modification of Bloom-Richardson system depends on following factors.
(1) Tumor tubule formation:
(i) One point: more than 75% of tumor.
(ii) Two points: 10-75% of tumor.
(iii) Three points: less than 10% of tumor.
(2) Number of mitotic figures in most active area. This is performed by counting 10 high-power fields. This should be performed by evaluating the areas with greatest atypia.
Scoring was carried out as follows.
(1) Three to five points: well differentiated (grade I).
(2) Six to seven points: moderately differentiated (grade II).
(3) Eight to nine points: poorly differentiated (grade III).
Immunohistochemical staining
The blocks were assessed immunohistochemically using a standard immunoperoxidase method (monoclonal CD10, dilution 1 : 50, pretreatment with Decloak 5 min in TRS; Novocastra, Newcastle upon Tyne, UK) and were achieved by a labeled streptavidin-biotin peroxidase complex method (Zymed Histostain Plus Kit; Zymed Laboratories, South San Francisco, California, USA). The formed complexes were visualized with aminoethyl carbazole chromogen/ substrate. CD10 immunostaining was recorded as negative, weakly positive, and strongly positive.
The negative control was obtained by omitting the primary antibody in each case.
For positive control, obtained from patient with acute lymphoblastic leukemia, which exhibits strong intensity of CD10 immunostaining, was used.
Evaluation of CD10 immunostaining
Every section was carefully examined at power magnification ( Â 100) for the presence of tumor stromal immunostaining using Olympus microscope CX21 (Mainland, China).
The CD10 immunostaining was scored quantitatively as negative when there was no tumor stromal staining, as weak positive when there was either diffuse weak staining or weak or strong focal staining in less than 30% of tumor stromal cells, and as strong positive when there was strong staining in 30% or more of tumor stromal cells (Makretsov et al., 2007) .
Statistical analysis
The significance of the results was assessed by determining the P value using the w 2 -test and one-way analysis of variance. P-value less than 0.05 was significant, P-value less than 0.01 was highly significant, P-value less than 0.001 was very highly significant and P-value more than 0.05 was not significant.
Results
The present study included 50 female cases of mammary duct carcinoma, 26 (52%) cases were removed by lumpectomy, while 24 (48%) cases were removed by radical mastectomy.
The majority of patients studied had invasive duct carcinoma, as they represented 36 patients (72%), whereas only two patients (4%) had duct carcinoma in situ. The rest of the patients showed extensive duct carcinoma in situ, with focal invasion (24%).
In invasive duct carcinoma patients, grade II represented the majority of patients studied (52.8%) followed by grade III (30.6%), whereas grade I represented only 16.6% of patients.
The majority of studied patients with mammary duct carcinoma were above the age of 40 years (82%), whereas patients below the age of 40 years represented only 18%.
The mean age of all mammary duct carcinoma patients studied was 49.12.
Only some patients with invasive duct carcinoma grade II (37%) and few patients with invasive duct carcinoma grade III (18%) were seen in the age group below 40 years. These results were insignificant.
The least mean age detected in invasive duct carcinoma grade III was 49.7, whereas the highest mean age seen in invasive duct carcinoma grade II was 67. Therefore, tumor grade was inversely proportionate with the mean age.
All patients with duct carcinoma in situ, 58.3% patients with extensive duct carcinoma in situ with focal invasion, and majority of all grades of invasive mammary duct carcinoma patients showed tumor sizes less than 5 cm in maximal diameter. However, these results were insignificant. The mean tumor size in all mammary duct carcinoma patients studied was 3.7 cm.
With respect to tumor grade, it showed inverse proportion with mean tumor size. The highest mean tumor size was seen in patients with extensive duct carcinoma in situ with focal invasion, whereas the lowest mean tumor size was seen in invasive duct carcinoma grade II patients.
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grade II patients. A high statistical significance for these results was detected (P < 0.05).
Most of the invasive duct carcinoma patients grades I and II and all patients with duct carcinoma in situ showed positive expression of estrogen receptor immunostaining. However, most of grade III invasive duct carcinoma patients showed negative estrogen and progesterone receptor expression. Her2/neu was expressed in less than half of all patients with invasive duct carcinoma. These results were statistically insignificant.
Most of the studied patients with extensive duct carcinoma in situ with focal invasion and invasive duct carcinoma grades II and III showed positive CD10 immunostaining. Meanwhile, half of the patients with duct carcinoma in situ and invasive duct carcinoma grade I were CD10 positive, which was statistically insignificant.
Strong stromal CD10 immunostaining was only seen in 71.4% of invasive duct carcinoma grade III patients, whereas all duct carcinoma in situ patients showed weak stromal CD10 immunostaining. There was a very high significant correlation between the intensity of stromal CD10 immunostaining and the tumor grade (P < 0.0002).
There was no difference between stromal CD10 immunostaining and different age groups of the studied patients. Furthermore, these results were not statistically significant (P > 0.05).
In addition, there was no statistically significant difference between stromal CD10 immunostaining intensity and tumor sizes in the studied patients (P > 0.05).
Strong stromal CD10 immunostaining was seen in only 25% of patients with metastatic lymph nodes, whereas negative CD10 immunostaining was seen in nodenegative patients. No statistical significance for these results was attained (P > 0.05) ( Table 1) .
Most of the estrogen, progesterone, and Her2/neu-positive patients showed weak CD10 immunostaining. Furthermore, no statistically significant correlation was noted between CD10 immunostaining intensity and hormone profile expression in the studied patients (P > 0.05).
Patients who were negative for stromal CD10 immunostaining were also negative for estrogen receptor staining (38.4%), whereas patients showing strong CD10 immunostaining showed equal distribution between negative and moderate estrogen receptor staining intensity (33.3% each). Nevertheless, these results showed no statistical significance (P > 0.05).
Negative progesterone receptor immunostaining was seen in most of CD10 negative patients (61.5%). However, no statistical significance was reached (P > 0.05) ( Table 2) .
Her2/neu-negative immunostaining was seen in the majority of patients, whether negatively stained for stromal CD10 (92.3%), weakly stained for CD10 (77.4%), or strongly stained for stromal CD10 (83.3%). These results were not statistically significant (P > 0.05) ( Fig. 1 ).
Discussion
Breast cancer is a major concern worldwide and is one of the leading causes of death in women (Putti et al., 2005) .
The estimated annual incidence of breast cancer worldwide is about 1 million patients (22% of all cancers in the world in 2000) (Dumitrescu and Cotarla, 2005) . According to the Egyptian National Cancer Institute, breast cancer constitutes about 33% of all Egyptian female cancers (EL Bolkainy et al., 2005) . It is considered the most common cancer among women worldwide, of which infiltrating duct carcinoma is the most frequent histological type, accounting for B68% of breast cancer patients (Subhawong et al., 2009 ).
Seventy-two percent of our studied patients were diagnosed as invasive duct carcinoma and 24% were diagnosed as extensive duct carcinoma in situ with focal invasion, whereas the remaining 4% were diagnosed as duct carcinoma in situ. Furthermore, the invasive duct carcinoma patients grade II represented majority of patients studied (52.8%) followed by grade III, which was diagnosed in 30.6% of patients, whereas grade I was diagnosed in only 16.6% of patients.
Our results were similar to those reported by Makretsov et al. (2007) , which was conducted on 452 patients with mammary duct carcinoma, in which invasive duct carcinoma comprised 258 patients. Grade II represented the majority of invasive duct carcinoma patients, as it was diagnosed in 53.8% of patients (139 patients) followed by grade III, which was diagnosed in 26.4% of patients (68 patients), whereas grade I was noted in 19.8% of patients (51 patients). Correspondingly, in the study conducted by Yamaguchi et al. (2008) , it was observed that the most prevalent grade was invasive duct carcinoma grade II, representing 40% of studied patients.
Our results were in contrast with those reported by Putti et al. (2005) , whose most prevalent grade of invasive duct carcinoma patients was grade III, which accounted for 94% of their studied patients, followed by grade II, which was found in 5% of their patients, whereas grade I was the least prevalent, accounting for only 1% of their patients. Furthermore, Lu et al. (2002) stated that the majority of their studied patients were diagnosed as invasive duct carcinoma grade III (75%) followed by grade II, which constituted 24% of their patients, whereas grade I represented only 1% of their studied patients.
In the present study, 82% of the studied patients were above the age of 40 years. The patients' age in the present study ranged from 25 to 70 years, with mean age of 49.12 ± 11.6. Similarly, in the study by Putti et al. (2005) , patients' age ranged from 25 to 70 years, with mean age of 50. In addition, Seventy-eight percent of our studied patients showed tumor size less than 5 cm in maximal diameter. They ranged from 1.5 to 13.5 cm in maximal diameter, with mean tumor size of 3.7 ± 2.57. Correspondingly, Lu et al. (2002) observed in their study that 89% of their patients showed tumor sizes less than 5 cm in maximal diameter. Tumor size in their study ranged from 0.6 to 11 cm in maximal diameter, with mean tumor size of 3.2. Van Der Vegt et al.
(2010) also reported that 93.5% of their studied patients showed tumor sizes less than 5 cm in maximal diameter.
However, much smaller tumor sizes were observed in the study conducted by Makretsov et al. (2007) , as 46.1% of their studied patients showed tumor sizes of 2 cm or less in maximal diameter, keeping in mind that 10.9% of their total patients were of unknown tumor sizes.
In contrast to our results, the study conducted by Putti et al. (2005) recorded that the majority (53%) of their studied patients showed tumor size greater than 5 cm in maximal diameter.
In this study, positive lymph node metastasis was seen in all patients with invasive duct carcinoma grade III, whereas it was negative in all invasive duct carcinoma grade I patients.
With respect to invasive duct carcinoma grade II patients, there was a slight predominance of lymph node negativity (53.9%). These results showed a highly significant correlation between tumor grade and lymph node metastasis (P < 0.01).
In contrast to our results, Xiaojing et al. (2006) revealed that 85% of their studied patients diagnosed as invasive duct carcinoma grades II and III showed positive axillary lymph node metastasis compared with 67% of invasive duct carcinoma patients grade I, and the difference was not statistically significant.
In the present study, we observed positive estrogen receptor expression in all patients with duct carcinoma in situ and in most of the invasive duct carcinoma patients grades I (83.3%) and II (84.2%). However, only 36.4% of patients with invasive duct carcinoma grade III and 41.7% of patients showing extensive duct carcinoma in situ with focal invasion showed estrogen receptor positivity. No significant correlation was found between tumor grade and estrogen receptor expression (P > 0.05).
Similarly, Arafah (2010) noted that the majority of invasive duct carcinoma grade I patients (88.9%) showed estrogen receptor positivity and most of the invasive duct carcinoma grade II patients (70.6%) were immunopositive to estrogen receptor compared with only 54.5% of invasive duct carcinoma grade III patients showing estrogen receptor positivity.
In our study, progesterone receptor positivity in all duct carcinoma in-situ patients and in majority of invasive duct carcinoma grade II patients (63.2%) was observed. In addition, only 33.3% of invasive duct carcinoma patients grade I, 36.4% of invasive duct carcinoma patients grade III, and 33.3% of extensive duct carcinoma in-situ patients with focal invasion showed progesterone receptor positivity. There was no statistically significant correlation found between tumor grade and progesterone receptor expression (P > 0.05).
In contrast to our results, Arafah (2010) noticed positive progesterone receptor immunohistochemical staining in most of the invasive duct carcinoma grade I patients (77.8%), 63.5% of invasive duct carcinoma grade II patients, and about half of invasive duct carcinoma grade III patients (48.8%). Furthermore, this study stated a statistically significant correlation between tumor grade and progesterone receptors immunohistochemical expression. The disparity between this result and ours may be attributed to the larger sample size (164 patients with invasive duct carcinoma in comparison with 36 in ours).
With respect to Her2/neu receptor, positive immunohistochemical expression was seen in less than half of all patients with invasive duct carcinoma grades II (42.1%) and III (9%), but none of the patients with invasive duct carcinoma grade I showed Her2/neu immunostaining. No significant correlation was observed in our study between tumor grade and Her2/neu receptor expression (P > 0.05). Concurrently, Arafah (2010) stated that the vast majority of their studied invasive duct carcinoma patients of all grades were Her2/neu receptor negative. Furthermore, they concluded that the correlation between Her2/ neu receptor immunoreactivity and the tumor grade was also insignificant. Similarly, Ivković-Kapicl et al. (2007) recorded that none of the invasive duct carcinoma grade I patients showed Her2/neu receptor positivity.
In contrast to our findings, Ivković-Kapicl et al. (2007) conducted a study on the expression of Her2/neu receptor in different grades of invasive duct carcinoma and concluded that there was a statistically significant correlation between Her2/neu receptor expression and tumor grade. They found Her2/neu receptor overexpression in less than half of patients with invasive duct carcinoma grade III (41%) and in 21% of invasive duct carcinoma grade II patients.
In this study, positive stromal CD10 immunostaining was observed in most of the patients diagnosed as extensive duct carcinoma in situ with focal invasion (66.7%) and invasive duct carcinoma grade II (94.7%) and grade III (63.6%) as opposed to only half of the patients (50%) diagnosed as invasive duct carcinoma grade I and duct carcinoma in situ.
Our results were insignificant with respect to the correlation between stromal CD10-positive immunostaining and tumor grade (P > 0.05). This may be explained by the small sample size in our study and the uneven distribution of the different grades of mammary duct carcinoma patients studied (two patients with duct carcinoma in situ vs. 12 patients with extensive duct carcinoma in situ with focal invasion vs. 36 patients with invasive duct carcinoma).
Similarly, Puri et al. (2011) , observed that most of their patients, of all grades, showed CD10 receptor positivity with an insignificant correlation between CD10 immunostaining positivity and tumor grade.
In contrast, Iwaya et al. (2002) , observed positive CD10 immunostaining in only 18% of invasive ductal carcinomas patients included in their study but in none of their noninvasive ductal carcinoma patients studied. Similarly, no statistically significant correlation was obtained between CD10 immunostaining positivity and tumor grade in their study.
In contrast to our results, Makretsov et al. (2007) found a significant correlation between CD10 immunostaining positivity and tumor grade, as they noticed that most of the invasive duct carcinoma patients were positively stained for CD10 compared with less than half of duct carcinoma in situ patients.
Our study achieved a highly significant correlation between the intensity of CD10 immunostaining and tumor grade (P < 0.01), as all patients diagnosed as duct carcinoma in situ, with or without focal invasion, as invasive duct carcinoma grade II, and most of the invasive duct carcinoma grade I patients (66.7%) showed weak immunostaining compared with invasive duct carcinoma grade III, in which 71.4% of the patients showed strong immunostaining.
Similarly, Makretsov et al. (2007) concluded that 94.3% of duct carcinoma in-situ patients were weakly stained for CD10, whereas strong CD10 immunostaining was found in 59% of invasive duct carcinoma grade III patients. In invasive duct carcinoma grades I and II, most of the patients showed weak staining. Their results were also statistically significant.
This statistically significant correlation between CD10 immunostaining intensity and tumor aggressiveness may be attributed to the fact that CD10, being one of the matrix metalloproteinases, cleaves the protein components of the extracellular matrix and thereby plays a central role in tissue remodeling. Therefore, in mammary duct carcinoma, CD10, by the degradation of the extracellular matrix, helps the tumor cells to invade the surrounding tissue stroma (Coussens et al., 2002) .
Our study did not achieve any significant correlation between stromal CD10 immunostaining intensity with respect to patients' age or tumor size. In accordance with our study, the results obtained by Makretsov et al. (2007) revealed the same insignificant correlation, as they concluded that neither patients' age nor tumor size correlated with stromal CD10 immunostaining intensity. Another study conducted by Iwaya et al. (2002) similarly showed insignificant correlation between stromal CD10 expression and patient's age, tumor size, or clinical stage of the tumor.
Most of the invasive duct carcinoma patients in our study, whether or not associated with lymph node metastasis, showed weak stromal CD10 immunostaining. A significant correlation between stromal CD10 immunostaining intensity and lymph node metastasis was not attained. Concurrently, Makretsov et al. (2007) also found that CD10 immunostaining intensity was not affected by the lymph node status.
Contradictory results were concluded by Iwaya et al. (2002) , who showed a significant correlation between lymph node metastasis and CD10 immunostaining expression, stating that the positivity as well as the intensity of CD10 stromal immunostaining were significantly higher in the patients associated with axillary lymph node metastasis.
Weak stromal CD10 immunostaining was observed in most of the patients, showing positive staining for estrogen, progesterone, and Her2/neu receptors (P > 0.05). An insignificant correlation between stromal CD10 immunostaining intensity and estrogen, progesterone, or Her2/neu receptors positivity, including their staining intensity, was observed in our study.
Similar conclusions were drawn by Makretsov et al. (2007) , concerning progesterone and Her2/neu receptors only. With respect to estrogen receptors, unlike our study, they were found to be negative in most of the CD10-positive patients (whether weak or strong intensity). A significant correlation between CD10 immunostaining intensity and estrogen receptors expression negativity was confirmed in their study. Puri et al. (2011) observed that majority of estrogen and progesterone receptor negative patients showed stromal CD10 receptor overexpression. They concluded that CD10 receptor immunostaining intensity did not significantly correlate with either estrogen or progesterone receptor expression.
In contrast to our results, Puri et al. (2011) stated that there was a strongly positive statistically significant correlation between CD10 expression and HER2-neu expression.
CD10 constitutes a clinically important prognostic marker and a potential target for the development of novel therapies. We concluded in our study that there was a highly significant correlation between tumor grade and lymph node metastasis. The higher the tumor grade the greater the incidence of lymph node metastasis. A highly significant correlation was also attained between the intensity of CD10 immunostaining and tumor grade. The CD10 immunostaining intensity was directly proportional to tumor grade. Most of the studied patients, irrespective of the tumor grade, were above the age of 40 years. However, no significant correlation was noticed between tumor grade and patients' age. Most of the tumor sizes, irrespective of the tumor grade, were less than 5 cm in maximal diameter. However, no significant correlation was noticed between tumor grade and tumor size. Furthermore, no significant correlation was found between tumor grade and estrogen, progesterone, or Her2/ neu receptor expression. No significant correlation was noticed between CD10 immunostaining intensity and patients' age, tumor size, lymph node status, and expression of estrogen, progesterone, or Her2/neu receptors. Lack of statistical significance attainment was most likely due to the limited number of studied patients. Further studies with larger number of patients are recommended to further validate these findings.
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